ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi gets Warp Drive aminoglycosides

by Lisa M. Jarvis
December 5, 2016 | APPEARED IN VOLUME 94, ISSUE 48

Sanofi has taken in-house an early-stage antibiotics program developed by its partner Warp Drive Bio. The novel aminoglycosides were discovered using Warp Drive’s genome mining technology, which involves searching the sequences of bacteria for gene clusters that encode for analogs of known antibiotics. Sanofi has been an investor in Warp Drive since 2012 and earlier this year agreed to pay up to $750 million for the rights to gram-negative antibiotics and molecules that modulate the oncology target Ras. Sanofi will be responsible for preclinical and clinical research for the aminoglycosides.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment